2023
Clinical
Trials and the Clinical Trials Regulation – impact on questions of
patentability at the EPO
James Warner and Cameron Marshall, Carpmaels
& Ransford (London)
Patent
enforcement in the UPC from a life sciences perspective: what will change?
Dr. Kai Rüting, Vossius & Partner (Munich); Daan
de Lange, Brinkhof Advocaten (Amsterdam)
AI tools
for patent attorneys: hallucination or reality?
Dr. Rachel Free, CMS Cameron McKenna Nabarro
Olswang LLP (London)
Adaptation
of the description under Art. 84 EPC and the potential consequences in European
patent litigation
Dr. Stephan
Neuhaus, Allen & Overy (Düsseldorf)
2022
Advanced UP/UPC Seminar: Case Studies
for the Life Science/Chemistry Sector
Dr. Thorsten
Bausch and Dr. Niels Hölder, Hoffmann Eitle (Munich)
Plausibility as a Means to Assess Quid
Pro Quo
Dr.
Hans-Rainer Jaenichen, Vossius & Partner (Munich)
Preliminary Injunctions Today
Dr. Andreas
von Falck, Hogan Lovells (Düsseldorf)
High Priority – Priority Entitlement in
the EPO
Dr. Derk Vos,
Maiwald (Munich)
2019
Arbitration of patent disputes in the
field of life sciences
Mr. Andrea
Mondini, Times Attorneys (Zurich)
Plausibility - A new criterion for
patentability?
Dr. Derk Vos,
Maiwald (Munich)
How to Deal with Unusual Prior Art in
the Determination of Inventive Step
Dr. Ulrike
Ciesla, MLL (Zurich); Dr. Thorsten Bausch, Hoffmann Eitle (Munich)
The changing Landscape of Patent
Eligibility in the U.S.
Dr. Kirsten
A. Grüneberg, Grüneberg and Myers PLLC (Washington)
Patenting Digital Health Inventions
Dr. A. Dick
and Dr. M. Stößel, Altmann Stößel Dick Patentanwälte PartG mbB (Mannheim)
2018
Patents and Biodiversity Legislations - What
patent practitioners need to know about the Nagoya Protocol.
Dr. Michael Kock, dr. kock
consulting (Basel)
Transparency vs Fair Protection - Is the
clinical trial-transparency initiative a deterrent to innovation?
Dr. Lorenz Kallenbach, Corporate
Patent Counsel at Merck (Darmstadt)
U.S. Patent Rights: Is the pendulum swinging back in favor of
patent owners?
Dr. Anthony Tridico, Finnegan (London)
Exhaustion of Patent Rights
Dr. Johann Pitz, Vossius & Partner (Munich)
Hindsight bias in patent law
Dr. Mark Schweizer, President of the Swiss Federal
Patent Court
An update on SPCs – what’s new?
David Miller and Christopher Hamer, Mathys
& Squire (London)
2017
Guarantees /warranties in the context of IP
related agreements
Marco Stief, Maiwald (Munich)
G 1/15 and partial priorities: consequences for
divisional filing strategies
Dr. Hans-Rainer Jaenichen and Dr. Jürgen
Meier, Vossius & Partner (Munich)
Protection of Know How, Trade Secrets and
Confidential Information
Sarah Turner, Hogan Lovells (London)
The Judicial Exceptions And Patent Eligibility
Dr. Kirsten A. Grüneberg, Grüneberg &
Meyrs PLLC (Washington DC)
European claim drafting: The importance (or
not) of precision
Chris Hamer, Mathys & Squire (London)
2016
2nd Medical Use Claims – New
Indications for an old Claim Category
Dr. U. Storz; Michalski, Hüttermann &
Partner (Düsseldorf)
Pharmaceutical & Biotech Patent Cases 2015
Year in Review
Brian Coggio, Fish & Richardson (New
York)
Indirect Patent Infringement in UK
Sebastian Moore, Herbert Smith
Freehills (London)
Recent Developments in the case law of the
Boards of Appeal of the EPO
Dr. Rudolf Teschemacher, Bardehle
Pagenberg (Munich)
Incentives of the Paediatric Extension
Regulation: Skinny Labelling – Latest Developments
Prof. Dr. Burkhard Sträter, Sträter
Rechtsanwälte (Bonn)
2015
Rules of Procedure in Opposition and Opposition
Appeal Proceedings at the EPO - A balancing act between procedural economy
and
the right to be heard
Dr.Eva Ehlich, Maiwald
Patentanwaltsgesellschaft mbH (Munich)
Disclaimers and Selection Inventions under EPC
practice
Dr. A. Hüttermann; Michalski, Hüttermann
& Partner (Düsseldorf)
Poisoned priorities and rays of hope from the
EPO
Dr. Tobias Bremi, Isler &
Pedrazzini AG, (Zürich), Second Ordinary Judge at the Swiss Federal Patent
Court
Patent disputes at the Interface of Patent and
Administrative Law in Switzerland
Dr. Simon Holzer and Mr. Christophe
Rapin, Meyerlustenberger Lachenal (Zürich)
Strategies for Successfully Navigating
Post-Grant Procedures at the USPTO
Dr. Anthony Tridico, Finnegan (London)
News relating to the Unitary Patent and
European Patent Court
Dr. Ulrich Blumenröder, Grünecker Patent-
und Rechtsanwälte (Munich)
2014
EU Competition Law and IPRs in Pharma
Mr. Blaž Višnar, Case Officer at the
Directorate General of Competition of the European Commission (Brussels)
Cross-border preliminary measures in patent
litigation and international arbitration in The Netherlands
Bert Oosting, Hogan Lovells
International LLP (Amsterdam)
Disclosure and Utility Requirements in Canadian
Patent Practice
Dr. John Norman, Gowlings (Ottawa)
The New EU Competition Rules For Licensing
Agreements
Prof. Dr. Andreas Heinemann, Dipl.-Ök., Lehrstuhl
für Handels-, Wirtschafts- und Europarecht; Universität Zürich
Compulsory Licenses
Dr. Roberto Romandini, Max Planck
Institute for Innovation and Competition (Munich)
2013
The pros and cons of AIA - How can we make
strategic use of it?
Dr. Anthony Tridico, Finnegan (Brussels)
The Impact of Employee Invention Law on
Research and Development Co-operations
Jens Kunzmann, Cornelius, Bartenbach,
Haesemann & Partner (Cologne)
Patent Litigation in Germany and Europe
Philipp Neels, Wallinger, Richer,
Schlotter, Tostmann (Munich)
Boards of Appeal of the EPO - quo vadis? In the
light of the Appeals to the German Constitutional Court and the Unified Patent
Court Project
Dr. U. Kinkeldey, Former Chair of a
TBA at the EPO and permanent member of the EBA at the EPO
The Unitary Patent and European Patent Court
Dr. Ulrich Blumenröder, Grünecker Patent-
und Rechtsanwälte (Munich)
European Case Law relating to SPCs
Dr. Stefan Danner, ZSP Patent Attorneys (Munich)
2012
The Common Law – Unified Patent Court –
Important UK Cases
The RT. Hon. Professor Sir Robin
Jacob, Faculty of Laws; University College London
The Therasense Case – a new approach regarding
inequitable conduct
Brief overview on important points of the
revision of the US patent law
Prof. Martin J. Adelman, George
Washington University Law School; Washington DC
Where does the EU stand on Biosimilars?
Marie Manley, Bristows (London)
Patent Litigation in Europe – Trends and
Outlook for Pharma Patents
Dr. Andreas von Falck, Hogan Lovells (Düsseldorf)
The Pitfalls of Art. 123 EPC - Recent
Developments in Case Law
Dr. Derk Vos, Maiwald (Munich)
First Experiences at the Swiss Federal Patent
Court
Dr. Dieter Brändle, President of the
Swiss Federal Patent Court
2011
Introduction
of the Swiss Federal Patent Court and Recent European Case Law on Selection
Inventions, Divisional Applications
and Double Patenting
Dr. Tobias Bremi, Isler & Pedrazzini AG, Zürich; elected Judge
at the Swiss Federal Patent Court
How to
efficiently perform FTO-Analysis with the help of intelligent IT
Gary J. Speier, Schwegman, Lundberg, Woessner (Minneapolis)
European
Court of Justice on Scope of Protection of DNA Sequences (Monsanto vs. Cefetra)
Dr. Michael Kock, Head Intellectual Property; Syngenta International
AG (Basel)
Patent
Litigation in Germany – Practical Aspects of Procedural Law
Dr. Peter Kather, Preu Bohlig & Partner (Düsseldorf)
Patent
Litigation in France – Decisions and Trends for Chemistry and Pharma Patents
Pierre Véron, Véron & Associés (Paris)
Research
Exemptions in the US, Europe, CN and JP
Kristof Roox, Crowell & Moring (Brussels)
2010
Patent
Mapping and Patent Landscaping
Dr. Reinhold Nowak, CEO of OMEGA Consulting Group GmbH (Adelshofen)
Strategic
Uses of U.S. Reexamination Proceedings
Jonathan Spadt, RatnerPrestia (Valley Forge, PA)
Written
Description Requirement in the U.S. Patent Practice
Brian D. Coggio, Fish & Richardson P.C. (New York)
IP Rights and
Licensing – Effects on Tax Law
Stephan Karl Schultze, LOEBA Treuhand GmbH, Lörrach
Technology-
and IP-Transfer with China
Dr. Michael Kock, Syngenta International AG (Basel)
Patent Law
Strategies Under Indian Practice
Pravin Anand, Anand & Anand (New Delhi)
2009
Patent Litigation in Europe – Trends and Outlook for
Pharma Patents
Dr. Andreas von Falck, Lovells (Düsseldorf)
Know How Protection and Patent Strategies of Globally
Active Companies – Evonik Degussa Experiences
Dr. Matthias Schäfer, Evonik Degussa GmbH (Hanau-Wolfgang)
The Attorney always rings Twice - First Experiences
with taking evidence under the Enforcement Directive in Germany
Dr. Mathias Ricker and Dr. Uli Foerstl, Wallinger Ricker Schlotter
Foerstl (Munich)
Successfully Structuring Out-Licensing and Spin-Out
Agreements by Pharma and Big Biotech:
How to Leverage Your Assets to Increase Revenues
Laura Anderson, Bristows (London)
The Patenting of Antibodies and their Medical Uses
under EPO Practice
Dr. Hans-Rainer Jaenichen, Vossius & Partner (Munich)
Patenting Stem Cells – Different Approaches in EP, DE
and UK
Dr. Jürgen Meier, Vossius & Partner (Munich)
2008
Inequitable conduct: What it is and how to avoid it
Prof. Brian D. Coggio, Fish & Richardson P.C. (New York)
Patents and Public Health - What is at stake? What is
the way forward?
Dr.Felix Addor, Swiss Federal Institute of Intellectual Property (Bern)
Licensing – Exclusive, Non-Exclusive, Sole, Minimums,
Warranties – How to Avoid Pitfalls
Prof. Dr. Heinz Goddar, Boehmert & Boehmert (Munich)
Essential Patents / FRAND – an objection in the
pharmaceutical sector?
Dr. Walter Maiwald, Maiwald Patentanwalts GmbH (Munich)
US Patent Infringement Case Law – Latest Developments
Robert J. Koch, Milbank, Tweed, Hadley & McCloy LLP (Munich/Washington
DC)
Interaction between Competition and Intellectual
Property Law
Sebastian Moore and Stephen Wisking, Herbert Smith LLP (London)
©
2024 Niizuma Wasner GmbH | Lörracherstr. 122 |
CH - 4125 Riehen | Tel.: +41 61 811 8903
Cookie-Hinweis Datenschutzerklärung AGB Impressum Disclaimer